Evidence map›Paper›PMID 42853933›Full record

ArticleScience advances2026

SUMO2 deletion changes chromatin accessibility and enhances cytotoxic T cell activation and tumor infiltration.

Mohottige D Neranjan Tharuka, Dai-Hua Chen, Maria Luisa Jurgensen Amaral, Tianchen Ren, Yixuan Kuang, Shih-Ting Huang, Nikhil Chilakapati, Bing Ren, Stephen P Schoenberger, Ye Zheng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohottige D Neranjan TharukaSchool of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.ORCID 0000-0003-4015-121X
Dai-Hua ChenDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92037, USA.ORCID 0000-0001-5785-6895
Maria Luisa Jurgensen AmaralDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92037, USA.
Tianchen RenDepartment of Chemistry, University of California, San Diego, La Jolla, CA 92037, USA.ORCID 0009-0009-5241-4022
Yixuan KuangDepartment of Chemistry, University of California, San Diego, La Jolla, CA 92037, USA.ORCID 0009-0004-3802-0418
Shih-Ting HuangDepartment of Chemistry, University of California, San Diego, La Jolla, CA 92037, USA.ORCID 0000-0003-3862-564X
Nikhil ChilakapatiDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92037, USA.ORCID 0009-0004-3456-8144
Bing RenNew York Genome Institute, New York, NY 10013, USA.ORCID 0000-0002-5435-1127
Stephen P SchoenbergerLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0002-9870-7340
Ye ZhengSalk Institute for Biological Sciences, La Jolla, CA 92037, USA.ORCID 0000-0001-5012-4309
Yuan ChenSchool of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.ORCID 0000-0002-1510-182X

Funding

Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple MyelomaR01CA212119 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, YUAN · 2017 to 2021
$2.8M
SUMO Modification and Cancer TherapyR01CA265410 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, YUAN · 2021 to 2025
$2.5M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
NCI NIH HHS R01 CA212119NCI NIH HHS R01 CA265410NIH HHS S10 OD026929
6 · The paper itself

Abstract

Cytotoxic T cells [cytotoxic lymphocytes (CTLs)] are crucial for adaptive immunity leading to prolonged survival and potential cures for cancer. Recent clinical data have shown that pharmacological inhibition modifies the tumor microenvironment (TME) and activates CTLs, although the mechanism is not well described. In this study, we found that T cell-specific knockout (KO) of the most prevalent SUMO paralog,

Indexed as

ChromatinGene DeletionLymphocyte ActivationLymphocytes, Tumor-InfiltratingNeoplasmsSmall Ubiquitin-Related Modifier ProteinsT-Lymphocytes, CytotoxicAnimalsCD8-Positive T-LymphocytesHumansMiceMice, KnockoutTumor MicroenvironmentChromatinSmall Ubiquitin-Related Modifier ProteinsSUMO2 protein, humanSUMO2 protein, mouse

Identifiers

PMID42853933
PMCPMC13651852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.